ArticleAmerican health & drug benefits2016

Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma.

Lisa A RaedlerPubMed ↗Full text ↗

No numbers read from the abstract.